Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: Evaluated by in vitro/in vivo live cell imaging

Journal of Controlled Release

Volumn 172, Issue 1, 2013, Pages 330-340

  Seynhaeve, Ann L B ^a   Dicheva, Bilyana M ^a   Hoving, Saske ^a   Koning, Gerben A ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Doxil; Intracellular release; Intracellular uptake; Live cell imaging; Lysosome

Indexed keywords

DOXIL; INTRACELLULAR RELEASE; INTRACELLULAR UPTAKE; LIVE-CELL IMAGING; LYSOSOME;

BIOCHEMISTRY; CELLS; CYTOLOGY; CYTOTOXICITY;

TUMORS;

DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL DENSITY; CELL ENCAPSULATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

DOXIL; INTRACELLULAR RELEASE; INTRACELLULAR UPTAKE; LIVE CELL IMAGING; LYSOSOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL NUCLEUS; DOXORUBICIN; HUMANS; LYSOSOMES; MELANOMA; MICE; MICROSCOPY; POLYETHYLENE GLYCOLS;

EID: 84884507408     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.08.034     Document Type: Article

References (40)

1. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992 (Pubitemid 24085451)
2. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284 (Pubitemid 30122932)
3. S.T. Duggan, and G.M. Keating Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma Drugs 71 2011 2531 2558
4. A.A. Gabizon, O. Lyass, G.J. Berry, and M. Wildgust Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies Cancer Invest. 22 2004 663 669 (Pubitemid 40064725)
5. M.S. Ewer, F.J. Martin, C. Henderson, C.L. Shapiro, R.S. Benjamin, and A.A. Gabizon Cardiac safety of liposomal anthracyclines Semin. Oncol. 31 2004 161 181 (Pubitemid 40023246)
6. E. Rivera, V. Valero, F.J. Esteva, L. Syrewicz, M. Cristofanilli, Z. Rahman, D.J. Booser, and G.N. Hortobagyi Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer Cancer Chemother. Pharmacol. 49 2002 299 302 (Pubitemid 34253268)
7. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler, and C.B.C.S. Group Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449 (Pubitemid 38444547)
8. I. Judson, J.A. Radford, M. Harris, J.Y. Blay, Q. van Hoesel, A. le Cesne, A.T. van Oosterom, M.J. Clemons, C. Kamby, C. Hermans, J. Whittaker, E. Donato di Paola, J. Verweij, and S. Nielsen Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 37 2001 870 877 (Pubitemid 32323965)
9. K.M. Laginha, S. Verwoert, G.J. Charrois, and T.M. Allen Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors Clin. Cancer Res. 11 2005 6944 6949 (Pubitemid 41428752)
10. T.O. Harasym, P.R. Cullis, and M.B. Bally Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes Cancer Chemother. Pharmacol. 40 1997 309 317 (Pubitemid 27276134)
11. M. Banciu, R.M. Schiffelers, and G. Storm Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil Pharm. Res. 25 2008 1948 1955
12. L.D. Mayer, G. Dougherty, T.O. Harasym, and M.B. Bally The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors J. Pharmacol. Exp. Ther. 280 1997 1406 1414 (Pubitemid 27166739)
13. A.L. Seynhaeve, S. Hoving, D. Schipper, C.E. Vermeulen, G. de Wiel-Ambagtsheer, S.T. van Tiel, A.M. Eggermont, and T.L. Ten Hagen Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response Cancer Res. 67 2007 9455 9462 (Pubitemid 47535935)
14. F. Szoka, F. Olson, T. Heath, W. Vail, E. Mayhew, and D. Papahadjopoulos Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes Biochim. Biophys. Acta 601 1980 559 571
15. G. Haran, R. Cohen, L.K. Bar, and Y. Barenholz Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1151 1993 201 215 (Pubitemid 23283973)
16. G.R. Bartlett Colorimetric assay methods for free and phosphorylated glyceric acids J. Biol. Chem. 234 1959 469 471
17. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112 (Pubitemid 20213250)
18. K.H. Falkvoll, E.K. Rofstad, T. Brustad, and P. Marton A transparent chamber for the dorsal skin fold of athymic mice Exp. Cell Biol. 52 1984 260 268 (Pubitemid 14107415)
19. H.D. Papenfuss, J.F. Gross, M. Intaglietta, and F.A. Treese A transparent access chamber for the rat dorsal skin fold Microvasc. Res. 18 1979 311 318 (Pubitemid 10180862)
20. F.A. Fornari, J.K. Randolph, J.C. Yalowich, M.K. Ritke, and D.A. Gewirtz Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol. Pharmacol. 45 1994 649 656 (Pubitemid 24139191)
21. A. Bodley, L.F. Liu, M. Israel, R. Seshadri, Y. Koseki, F.C. Giuliani, S. Kirschenbaum, R. Silber, and M. Potmesil DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA Cancer Res. 49 1989 5969 5978 (Pubitemid 19274156)
22. V.Y. Chen, M.M. Posada, L. Zhao, and G.R. Rosania Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance Pharm. Res. 24 2007 2156 2167 (Pubitemid 47493579)
23. K.K. Karukstis, E.H. Thompson, J.A. Whiles, and R.J. Rosenfeld Deciphering the fluorescence signature of daunomycin and doxorubicin Biophys. Chem. 73 1998 249 263 (Pubitemid 28337019)
24. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
25. R.K. Jain Delivery of novel therapeutic agents in tumors: physiological barriers and strategies J. Natl. Cancer Inst. 81 1989 570 576 (Pubitemid 19104487)
26. M. Leunig, F. Yuan, M.D. Menger, Y. Boucher, A.E. Goetz, K. Messmer, and R.K. Jain Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice Cancer Res. 52 1992 6553 6560
27. Q. Chen, A. Krol, A. Wright, D. Needham, M.W. Dewhirst, and F. Yuan Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome Int. J. Hyperthermia 24 2008 475 482
28. N.Z. Wu, R.D. Braun, M.H. Gaber, G.M. Lin, E.T. Ong, S. Shan, D. Papahadjopoulos, and M.W. Dewhirst Simultaneous measurement of liposome extravasation and content release in tumors Microcirculation 4 1997 83 101 (Pubitemid 127717669)
29. L. Li, T.L. ten Hagen, D. Schipper, T.M. Wijnberg, G.C. van Rhoon, A.M. Eggermont, L.H. Lindner, and G.A. Koning Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia J. Control. Release 143 2010 274 279
30. B.M. Dicheva, T.L. Hagen, L. Li, D. Schipper, A.L. Seynhaeve, G.C. Rhoon, A.M. Eggermont, L.H. Lindner, and G.A. Koning Cationic Thermosensitive Liposomes: A Novel Dual Targeted Heat-Triggered Drug Delivery Approach for Endothelial and Tumor Cells Nano Lett. 13 2013 2324 2331
31. A.A. Manzoor, L.H. Lindner, C.D. Landon, J.Y. Park, A.J. Simnick, M.R. Dreher, S. Das, G. Hanna, W. Park, A. Chilkoti, G.A. Koning, T.L. ten Hagen, D. Needham, and M.W. Dewhirst Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors Cancer Res. 72 2012 5566 5575
32. B. Geers, H. Dewitte, S.C. De Smedt, and I. Lentacker Crucial factors and emerging concepts in ultrasound-triggered drug delivery J. Control. Release 164 2012 248 255
33. A. Delalande, A. Bouakaz, G. Renault, F. Tabareau, S. Kotopoulis, P. Midoux, B. Arbeille, R. Uzbekov, S. Chakravarti, M. Postema, and C. Pichon Ultrasound and microbubble-assisted gene delivery in Achilles tendons: long lasting gene expression and restoration of fibromodulin KO phenotype J. Control. Release 156 2011 223 230
34. H. Fattahi, S. Laurent, F. Liu, N. Arsalani, L. Vander Elst, and R.N. Muller Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics Nanomedicine 6 2011 529 544
35. L. Li, T.L. Ten Hagen, M. Bolkestein, A. Gasselhuber, J. Yatvin, G.C. van Rhoon, A.M. Eggermont, D. Haemmerich, and G.A. Koning Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia J. Control. Release 167 2013 130 137
36. M. Kullberg, J.L. Owens, and K. Mann Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes J. Drug Target. 18 2010 313 320
37. D. Goren, A.T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, and A. Gabizon Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump Clin. Cancer Res. 6 2000 1949 1957 (Pubitemid 30305094)
38. M. van Lummel, W.J. van Blitterswijk, S.R. Vink, R.J. Veldman, M.A. van der Valk, D. Schipper, B.M. Dicheva, A.M. Eggermont, T.L. ten Hagen, M. Verheij, and G.A. Koning Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors FASEB J. 25 2011 280 289
39. L.R. Pedrosa, A. van Hell, R. Suss, W.J. van Blitterswijk, A.L. Seynhaeve, W.A. van Cappellen, A.M. Eggermont, T.L. Ten Hagen, M. Verheij, and G.A. Koning Improving intracellular Doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids Pharm. Res. 30 2013 1883 1895
40. Y. Zhao, D.Y. Alakhova, J.O. Kim, T.K. Bronich, and A.V. Kabanov A simple way to enhance Doxil(R) therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer J. Control. Release 168 2013 61 69